ERLIN2 and familial pancreatic carcinoma: We also tested BGJ398 sensitivity in 3 pancreatic cancer PDOs, including 1 (HO219) with a FGFR1-ERLIN2 chromosomal fusion (Supplemental Figure 5D), and observed increased sensitivity to BGJ398 in HO219 compared with 2 FGFR–wild-type PDAC PDOs (Supplemental Figure 5E).